The development of endocrine therapy for women with breast cancer

Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893, 10.1002/ijc.25516 Jemal, 2010, Cancer Statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 Beatson, 1896, On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases, Lancet, 2, 105 Huggins, 1952, Inhibition of human mammary and prostatic cancers by adrenalectomy, Cancer Res, 12, 134 Olivecrona, 1957, Experiences with hypophysectomy in cancer of the breast, Ann R Coll Surg Eng, 20, 267 Adair, 1946, The use of testosterone propionate in the treatment of advanced carcinoma of the breast, Ann Surg, 123, 1023, 10.1097/00000658-194606000-00006 Rae, 1948, Stilboestrol in late malignant disease of the breast, Glasgow Med J, 29, 248 Greenspan, 1963, Response of advanced breast cancer to the combination of the anti-metabolite methotrexate and the alkylating agent thiotepa, J Mt Sinai Hosp, 30, 246 Carter, 1977, Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group, JAMA, 237, 2079, 10.1001/jama.1977.03270460065023 Cline, 1963, Cancer studies. Cancer of the breast., Cal Med, 99, 393 Cole, 1971, A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474, Br J Cancer, 25, 270, 10.1038/bjc.1971.33 Osborne, 1998, Tamoxifen in the treatment of breast cancer, N Engl J Med, 339, 1609, 10.1056/NEJM199811263392207 Burstein, 2010, American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer, J Clin Oncol, 28, 3784, 10.1200/JCO.2009.26.3756 Ingle, 1981, Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer, N Engl J Med, 304, 16, 10.1056/NEJM198101013040104 Stewart, 1980, The tamoxifen trial a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer, Eur J Cancer, 83 Westerberg, 1980, Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial, Cancer Treat Rep, 64, 117 Ward, 1973, Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels, Br Med J, 1, 13, 10.1136/bmj.1.5844.13 Manni, 1980, Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy, Cancer, 46, 2838, 10.1002/1097-0142(19801215)46:12+<2838::AID-CNCR2820461421>3.0.CO;2-A Fisher, 2001, Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer, J Natl Cancer Inst Monogr, 62, 10.1093/oxfordjournals.jncimonographs.a003463 1985, Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years., Lancet, 325, 836, 10.1016/S0140-6736(85)92206-8 Fisher, 1989, A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors, N Engl J Med, 320, 479, 10.1056/NEJM198902233200802 Dignam, 1998, Early stopping of a clinical trial when there is no evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project, Control Clin Trials, 19, 575, 10.1016/S0197-2456(98)00041-5 Fisher, 2001, Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial, J Natl Cancer Inst, 93, 684, 10.1093/jnci/93.9.684 Stewart, 1992, The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group, J Natl Cancer Inst Monogr, 117 Stewart, 2001, Scottish adjuvant tamoxifen trial: a randomized study updated to 15years, J Natl Cancer Inst, 93, 456, 10.1093/jnci/93.6.456 Pritchard, 1980, Tamoxifen therapy in premenopausal patients with metastatic breast cancer, Cancer Treat Rep, 64, 787 Sawka, 1986, Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma, Cancer Res, 46, 3152 1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 2004, Tamoxifen for early breast cancer (Cochrane Review), 1 Lavie, 2008, The risk of developing uterine sarcoma after tamoxifen use, Int J Gynecol Cancer, 18, 352, 10.1111/j.1525-1438.2007.01025.x Fisher, 1998, Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371 Cuzick, 2002, First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial, Lancet, 360, 817, 10.1016/S0140-6736(02)09962-2 Cuzick, 2007, Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial, J Natl Cancer Inst, 99, 272, 10.1093/jnci/djk049 Fagerlin, 2010, Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid, Breast Cancer Res Treat, 119, 613, 10.1007/s10549-009-0618-4 Lewis, 2010, Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer, Cancer, 116, 2307 Fareston summary of product characteristics. Available at <http://www.medicines.org.uk/emc/medicine/10221/SPC/Fareston+60mg+Tablets>; 2010 [accessed 12.03.12 Martino, 2004, Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene, J Natl Cancer Inst, 96, 1751, 10.1093/jnci/djh319 Dickler, 2001, The MORE trial: multiple outcomes for raloxifen evaluation - breast cancer as a secondary end point: implications for prevention, Ann N Y Acad Sci, 949, 134, 10.1111/j.1749-6632.2001.tb04011.x Vogel, 2006, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial, JAMA, 295, 2727, 10.1001/jama.295.23.joc60074 Evista prescribing information. Available at <http://www.pi.lilly.com/us/evista-pi.pdf>; 2010 [accessed 12.03.12]. Vogel, 2010, Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer, Cancer Prev Res (Phila), 3, 696, 10.1158/1940-6207.CAPR-10-0076 Spicer, 1994, Sex steroids and breast cancer prevention, J Natl Cancer Inst Monogr, 139 Tan, 2008, The role of ovarian ablation in the adjuvant therapy of breast cancer, Curr Oncol Rep, 10, 27, 10.1007/s11912-008-0006-y Rabaglio, 2007, Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference, Lancet Oncol, 8, 940, 10.1016/S1470-2045(07)70317-0 McDonald Wade, 2008, Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings, Oncology, 75, 192, 10.1159/000163059 Baum, 2006, Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study, Eur J Cancer, 42, 895, 10.1016/j.ejca.2005.12.013 Hackshaw, 2009, Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer, J Natl Cancer Inst, 101, 341, 10.1093/jnci/djn498 Jonat, 2002, Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study, J Clin Oncol, 20, 4628, 10.1200/JCO.2002.05.042 Kaufmann, 2003, Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer, Eur J Cancer, 39, 1711, 10.1016/S0959-8049(03)00392-7 Cuzick, 2007, Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials, Lancet, 369, 1711, 10.1016/S0140-6736(07)60778-8 Karlsson, 2011, Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer, Ann Oncol, 22, 2216, 10.1093/annonc/mdq735 Miller, 2008, Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?, Oncologist, 13, 829, 10.1634/theoncologist.2008-0055 Harris, 1982, Aminoglutethimide in the treatment of advanced postmenopausal breast cancer, Cancer Res, 42, 3405s Buzdar, 1996, Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group., J Clin Oncol, 14, 2000, 10.1200/JCO.1996.14.7.2000 Buzdar, 1998, Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group., Cancer, 83, 1142, 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7 Gershanovich, 1998, Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3), Ann Oncol, 9, 639, 10.1023/A:1008226721932 Dombernowsky, 1998, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate, J Clin Oncol, 16, 453, 10.1200/JCO.1998.16.2.453 Nabholtz, 2000, Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group., J Clin Oncol, 18, 3758, 10.1200/JCO.2000.18.22.3758 Bonneterre, 2000, Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study, J Clin Oncol, 18, 3748, 10.1200/JCO.2000.18.22.3748 Mouridsen, 2001, Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group, J Clin Oncol, 19, 2596, 10.1200/JCO.2001.19.10.2596 Paridaens, 2008, Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group, J Clin Oncol, 26, 4883, 10.1200/JCO.2007.14.4659 Gltick, 2005, Changing the gold standard in adjuvant therapy for breast cancer: from tamoxifen to aromatase inhibition, Biomed Pharmacother, 59, S321 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 2005, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer, Lancet, 365, 60, 10.1016/S0140-6736(04)17666-6 2005, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, N Engl J Med, 353, 2747, 10.1056/NEJMoa052258 Coombes, 2004, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N Engl J Med, 350, 1081, 10.1056/NEJMoa040331 Cuzick, 2010, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol, 11, 1135, 10.1016/S1470-2045(10)70257-6 2009, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer, N Engl J Med, 361, 766, 10.1056/NEJMoa0810818 Colleoni, 2011, Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, J Clin Oncol, 29, 1117, 10.1200/JCO.2010.31.6455 Dowsett, 2010, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen, J Clin Oncol, 28, 509, 10.1200/JCO.2009.23.1274 Boccardo, 2006, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial, Ann Oncol, 17, vii10, 10.1093/annonc/mdl941 Jakesz, 2005, Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, Lancet, 366, 455, 10.1016/S0140-6736(05)67059-6 Kaufmann, 2007, Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study, J Clin Oncol, 25, 2664, 10.1200/JCO.2006.08.8054 Jonat, 2006, Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis, Lancet Oncol, 7, 991, 10.1016/S1470-2045(06)70948-2 2005, BIG 1–98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor- positive breast cancer, The Breast, 14, S3 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Goss, 2005, Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17, J Natl Cancer Inst, 97, 1262, 10.1093/jnci/dji250 Jakesz, 2007, Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast cancer and colorectal cancer study group trial 6a, J Natl Cancer Inst, 99, 1845, 10.1093/jnci/djm246 Mamounas, 2008, Benefit From exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat.analysis of the national surgical adjuvant breast and bowel project B-33 trial, J Clin Oncol, 26, 1965, 10.1200/JCO.2007.14.0228 Wakeling, 1991, A potent specific pure antiestrogen with clinical potential, Cancer Res, 51, 3867 Howell, 2002, Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment, J Clin Oncol, 20, 3396, 10.1200/JCO.2002.10.057 Cano, 1989, Tamoxifen and the uterus and endometrium, Lancet, 1, 376 Ewer, 2009, A woman’s heart: the impact of adjuvant endocrine therapy on cardiovascular health, Cancer, 115, 1813, 10.1002/cncr.24219 Santen, 2011, Clinical review: effect of endocrine therapies on bone in breast cancer patients, J Clin Endocrinol Metab, 96, 308, 10.1210/jc.2010-1679 Osborne, 2002, Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial, J Clin Oncol, 20, 3386, 10.1200/JCO.2002.10.058 Robertson, 2003, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials, Cancer, 98, 229, 10.1002/cncr.11468 Howell, 2004, Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial, J Clin Oncol, 22, 1605, 10.1200/JCO.2004.02.112 DeFriend, 1994, Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer, Cancer Res, 54, 408 Robertson, 2001, Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer, Cancer Res, 61, 6739 Di Leo, 2010, Results of the CONFIRM Phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer, J Clin Oncol, 28, 4594, 10.1200/JCO.2010.28.8415 Price, 2005, Clinical trial update: international breast cancer study group, Breast Cancer Res, 7, 252, 10.1186/bcr1334 Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285 Van Tine, 2011, ER and PI3K independently modulate endocrine resistance in ER positive breast cancer, Cancer Discov, 1, 287, 10.1158/2159-8290.CD-11-0192 McCartan, 2012, Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer, Cancer Res, 72, 220, 10.1158/0008-5472.CAN-11-1976 Giuliano, 2011, Biological mechanisms and clinical implications of endocrine resistance in breast cancer, Breast, 20, S42, 10.1016/S0960-9776(11)70293-4 Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: A GINECO randomized Phase II Trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Abstract presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 8–12 December, 2010 (Abstract S1–6). Baselga, 2012, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, 366, 520, 10.1056/NEJMoa1109653 Osborne, 2011, Mechanisms of endocrine resistance in breast cancer, Annu Rev Med, 62, 233, 10.1146/annurev-med-070909-182917 Osborne, 2005, Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer, Clin Cancer Res, 11, 865s, 10.1158/1078-0432.865s.11.2 Emde, 2011, Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance, Transl Oncol, 4, 293, 10.1593/tlo.11127 Wang, 2011, Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers – role of estrogen receptor and HER2 reactivation, Breast Cancer Res, 13, R121, 10.1186/bcr3067 Schwartzberg, 2010, Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer, Oncologist, 15, 122, 10.1634/theoncologist.2009-0240 Oh, 2001, Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells, Mol Endocrinol, 15, 1344, 10.1210/me.15.8.1344 Bayliss, 2007, Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response, Clin Cancer Res, 13, 7029, 10.1158/1078-0432.CCR-07-0587 Trimarchi, 2011, Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance, Chin J Cancer, 30, 749, 10.5732/cjc.011.10128 Wang, 2010, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors, Cancer Res, 70, 319, 10.1158/0008-5472.CAN-09-3224 Cancer Research UK. Statistics and outlook for breast cancer. Available at <http://www.cancerhelp.cancerresearchuk.org/type/breast-cancer/treatment/statistics-and-outlook-for-breast-cancer>; 2011 [accessed 12.03.12].